4502 JP3463000004

Report

Delayed Japan Exchange - 02:00 2022-06-27 am EDT
3776.00	JPY		+1.86%

06:02a	Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine	BU
06/24	Takeda Pharmaceutical to Absorb Businesses From Unit Nihon Pharmaceutical	MT
06/22	Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts	BU

News

Press Releases

Official Publications

Sector news

MarketScreener Strategies

Communiqués de presse de la société TAKEDA PHARMACEUTICAL COMPANY LIMITED

06:02a	Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficienc..	BU
06/22	Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation..	BU
06/10	Takeda's Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Th..	AQ
06/10	TAKEDA PHARMACEUTICAL : Notice Concerning Disposal of Treasury Shares under the Long-Term ..	PU
06/09	Takeda's Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Th..	BU
06/07	Takeda Canada applauds Quebec's new Rare Disease Policy	AQ
06/02	Takeda Pharmaceutical Company Limited - Notice Concerning Withdrawal of Shelf Registrat..	AQ
05/31	Takeda and Moderna Announce Plans to Transfer Marketing Authorization for SpikevaxTM CO..	AQ
05/31	Takeda Presents Latest Research from Oncology Portfolio and Pipeline at ASCO & EHA	BU
05/31	TAKEDA PHARMACEUTICAL : Current Report by Foreign Issuer (Form 6-K)	PU
05/31	TAKEDA PHARMACEUTICAL : Current Report by Foreign Issuer (Form 6-K)	PU
05/31	Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax&trad..	BU
05/27	TAKEDA PHARMACEUTICAL : and Seagen to Highlight ADCETRIS Combination Data	PU
05/26	Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Signifi..	BU
05/11	Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022	BU
04/28	CENTOGENE and Takeda Extend Market Access and Expansion Partnership to Advance Patient ..	AQ
04/27	Takeda Recognized as 2022 ISPE Facility of the Year Awards Winner in Two Categories	AQ
04/26	Takeda Holds Fourth Quarter and Full-Year FY2021 Earnings Call on May 11	AQ
04/26	Takeda Recognized as the 2022 ISPE Facility of the Year Awards Winner in Two Categories	BU
04/25	TAKEDA PHARMACEUTICAL : Holds Fourth Quarter and Full-Year FY2021 Earnings Call on May 1	PU
04/22	Takeda Presents New Exploratory Analysis Showing Patients Treated With LIVTENCITY&trade..	BU
04/19	Takeda's TAKHZYRO (lanadelumab-flyo) Prefilled Syringe Now Available for People With He..	AQ
04/18	Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and Booster Immuni..	BU
04/18	Takeda's TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for People With H..	BU
04/13	Takeda Announces Completion of Acquisition of Own Shares	BU
04/12	Takeda's TAKHZYRO® (lanadelumab) Open Label Phase 3 Study Met Its Objectives in Childre..	BU
04/09	Exclusive Speaker Interview with Ester Lovsin Barle Ahead of the 6th Annual Highly Pote..	AQ
04/05	Takeda and the New York Academy of Sciences Announce 2022 Innovators in Science Award W..	BU
04/04	Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting	AQ
04/01	Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting	BU
03/29	Takeda's TAKHZYRO (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attacks..	AQ
03/28	Takeda's TAKHZYRO® (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attack..	BU
03/01	Takeda - Interim Phase 4 Data Support TAKHZYRO (lanadelumab) as an Effective Treatment ..	AQ
02/28	Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduc..	BU
02/21	Takeda - Alofisel(darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Rea..	AQ
02/18	Alofisel®▼ (darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Rea..	BU
02/16	Ipsen - Cabometyx in combination with Opdivo demonstrated continued survival and qualit..	AQ
02/10	Takeda's Ramona Sequeira Becomes Board Chair of PhRMA	AQ
02/10	Takeda Receives U.S. FDA Approval for Prefilled Syringe Presentation of TAKHZYRO (lanad..	AQ
02/04	Takeda Pharmaceutical - Notice of the Revised Forecast of Consolidated Financials for F..	AQ
02/03	Takeda Pharmaceutical Company Limited - Notice of the Revised Forecast of Consolidated ..	AQ
02/03	Takeda Announces Strategic Leadership Changes to Help Drive Continued Growth and Compet..	AQ
02/03	TAKEDA PHARMACEUTICAL : Announces Strategic Leadership Changes	PU
02/03	Takeda Delivers Strong Third Quarter FY2021 Results and Raises Full-Year Forecast Refle..	BU
02/03	TAKEDA PHARMACEUTICAL : Summary of Financial Statements for the Nine-months Period Ended D..	PU
02/03	TAKEDA PHARMACEUTICAL : Provides Update on Status of Acquisition of Own Shares	PU
02/03	TAKEDA PHARMACEUTICAL : Notice of the Revised Forecast of Consolidated Financials for FY20..	PU
02/03	TAKEDA PHARMACEUTICAL COMPANY LIMITE : Notice of the Revised Forecast of Consolidated Fina..	EQ
02/01	FDA Approves Prophylactic Treatment with VONVENDI for Adult Patients Living with Sever..	AQ
01/31	FDA Approves Prophylactic Treatment with VONVENDI® [von Willebrand Factor (Recombinant)..	BU
01/27	TAKEDA PHARMACEUTICAL : Selects Four New Partners for Annual Global Corporate Social Respo..	PU
01/24	Takeda to Hold Third Quarter FY2021 Earnings Conference Call	AQ
01/21	TAKEDA PHARMACEUTICAL : to Hold Third Quarter FY2021 Earnings Conference Call	PU
01/19	Takeda Named Global Top Employer for Fifth Consecutive Year	BU
01/12	Takeda Emphasizes Strategy for Delivering Sustainable Growth Over Next Decade at the 40..	AQ
01/11	Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta T Cell Engager ..	AQ
01/10	PRESENTATION : Better health for people, Brighter future for the world	PU
01/10	TAKEDA PHARMACEUTICAL : Emphasizes Strategy for Delivering Sustainable Growth Over Next De..	PU
01/10	Takeda Emphasizes Strategy for Delivering Sustainable Growth Over Next Decade at the 40..	BU
01/10	Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ..	BU
01/05	Takeda to Present at The 40th Annual J.P. Morgan Healthcare Conference	AQ
01/05	TAKEDA PHARMACEUTICAL : to Present at The 40th Annual JP Morgan Healthcare Conference	PU
2021	TAKEDA PHARMACEUTICAL : Moderna and the Japanese Government Collaborate to Increase Modern..	PU
2021	Takeda Receives Complete Response Letter from the U.S. FDA for TAK-721	BU
2021	Takeda Receives Positive CHMP Opinion for Vedolizumab IV for the Treatment of Active Ch..	AQ
2021	Takeda Receives Positive CHMP Opinion for Vedolizumab IV for the Treatment of Active Ch..	BU
2021	Takeda Pharmaceutical - Maintaining trust in science is crucial to public health. Here'..	AQ
2021	GENERAL ANNOUNCEMENT : :Takeda Submits New Drug Application for Novavax COVID-19 Vaccine C..	PU
2021	TAKEDA PHARMACEUTICAL : Submits New Drug Application for Novavax' COVID-19 Vaccine Candida..	PU
2021	URGENT : Japan gov't panel OKs Moderna's COVID-19 vaccine as booster	AQ
2021	Takeda Drives Continued Scientific Leadership through Real-World Evidence in Rare Hemat..	AQ
2021	GENERAL ANNOUNCEMENT : :Share Repurchase Report (From November 1, 2021 to November 30, 202..	PU
2021	Takeda Drives Continued Scientific Leadership Through Real-World Evidence in Rare Hema..	BU
2021	Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENC..	AQ
2021	Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENC..	BU

1 2 3 4 5 6 7 8 9 10 Next

Analysis

Takeda, Nintendo among Japanese firms quietly celebrating weak yen